15.64

4.06% 0.61

Generate Biomedicines Inc (GENB)

Overview News Price History Discussions Forecast

Generate Biomedicines Inc stock is traded at $15.64, with a volume of 306.10K. It is up +4.06% in the last 24 hours and up +10.06% over the past month. Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Previous Close:

$15.03

Open:

$14.99

24h Volume:

306.10K

Relative Volume:

0.38

Market Cap:

$2.01B

Revenue:

Net Income/Loss:

P/E Ratio:

-7.2562

EPS:

-2.1554

Net Cash Flow:

1W Performance:

+8.99%

1M Performance:

+10.06%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$14.56

$15.70

1-Week Range:

$14.09

$15.70

52-Week Range:

$11.00

$18.18

Generate Biomedicines Inc Stock (GENB) Company Profile

Name

Generate Biomedicines Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

888-469-0055

Address

101 SOUTH STREET, SUITE 900, SOMERVILLE

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

GENB's Discussions on Twitter

Compare GENB vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GENB Generate Biomedicines Inc	15.64	1.94B	0	0	0	-2.1554
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	H.C. Wainwright	Buy
Mar-24-26	Initiated	Cantor Fitzgerald	Overweight
Mar-24-26	Initiated	Goldman	Buy
Mar-24-26	Initiated	Guggenheim	Buy
Mar-24-26	Initiated	Morgan Stanley	Overweight
Mar-24-26	Initiated	Piper Sandler	Overweight

View All

Generate Biomedicines Inc Stock (GENB) Latest News

Aug 14, 2026

Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat

Aug 14, 2026

Aug 11, 2026

Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat

Aug 11, 2026

Aug 08, 2026

Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat

Aug 08, 2026

Aug 07, 2026

Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo

Aug 07, 2026

Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat

Aug 07, 2026

Aug 06, 2026

Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com

Aug 06, 2026

Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com

Aug 06, 2026

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo

Aug 06, 2026

Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com

Aug 06, 2026

Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView

Aug 06, 2026

Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView

Aug 06, 2026

GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView

Aug 06, 2026

Generate Biomedicines (GENB) posts Q2 loss but holds $457.4M cash after IPO - Stock Titan

Aug 06, 2026

Aug 02, 2026